- Breast Cancer
- Blood Cancer
- Liver Cancer
- Brain cancer
- Colorectal Cancer
- Others
Cancer Monoclonal Antibodies Market size was valued at USD 54.2 billion in 2023 and is expected to grow at a CAGR of 11.8% from 2024-2030. A monoclonal antibody drug in cancer treatments engages natural immune system functions to fight cancer. Cancer monoclonal antibodies may be used in combination with other cancer treatments. An antibody attaches itself to a specific molecule (antigen) on the surface of a cancer cell when the antibody binds to an antigen, it acts as a flag to attract disease-fighting molecules or as a trigger that promotes the destruction of cancer cells by another immune system process. Due to its specificity, monoclonal antibodies have the least adverse effects than other cancer-treating drugs. Currently cancer monoclonal antibodies market is witnessing significant growth. Targeted and combination therapy drugs are leading in the market. Several market players collaborating to develop antibody drugs to treat various types of cancers. In January 2017, AbCellera Biologics, Inc. collaborated with Pfizer Inc. for a new therapeutic antibody discovery. AbCellera will use its monoclonal antibody (mAb) screening techniques in the discovery of function-modulating antibodies against undisclosed membrane protein targets. Academic institutions and organizations like the National Institute of Health (USA), the National Cancer Institute (USA), and many others are collaborating and participating in cancer research and awareness activities.
Cancer Monoclonal Antibodies Market Key Developments:
In May 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval to AstraZeneca's durvalumab (IMFINZI) for the treatment of patients with locally advanced or metastatic urothelial carcinoma In 2016, U.S Food and Drug Administration (FDA) approved Genentech Oncology's tecentriq (atezolizumab) for the treatment of patients with metastatic non-small cell lung cancer.
Global Cancer Monoclonal Antibodies Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
11.8%
Largest Market
North America
Fastest Growing Market
Asia Pacific
Cancer Monoclonal Antibodies Market Dynamics
The market growth of cancer monoclonal antibodies is driven by increased prevalence of cancer worldwide. According to WHO, cancer is one of the leading cause of deaths worldwide. In 2012, there were around 14 Mn new cases of cancer, 8.2 Mn people died because of cancer and numbers of new cancer cases are projected to rise 70% in coming decades. In addition, monoclonal antibodies are proved to be having less adverse effects when compared to conventional non-targeted therapies. Increasing investment in the development of monoclonal antibodies, technological advancements that enabling the genetic sequencing and increasing specificity of the antibodies are fueling the sales revenue ofcancer monoclonal antibodies market. However, the high cost of development, stringent regulatory guidelines, long period of clinical trials, are some of the factors hinder growth of cancer monoclonal antibodies market.
North-America Got Significant Share
Cancer Monoclonal Antibodies Market Regional Analysis
Geographically cancer monoclonal antibodies market has been segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America cancer monoclonal antibodies market is growing at a steady rate due to increased prevalence of various cancers and higher acceptance of existing monoclonal antibodies among healthcare professionals in the region. According to National Cancer Institute (NIH), an estimated 1,685,210 new cases of cancer were diagnosed in the United States and 595,690 people will die from the disease in 2016. Asia-Pacific region is expected to exhibit rapid growth due to rise in government spending on healthcare infrastructure, increasing R&D spending by companies and growing patient and healthcare professional awareness in therapeutic use of monoclonal antibodies in treatment of cancer. For instance, Government-led fund providers, such as National Natural Science Foundation and National Basic Research Program of China, offer financial support to enterprises and universities to conduct monoclonal antibody research and development. The presence of healthcare regulations and procedures to promote early treatment of diseases using advanced therapeutics and public policies to support early screening and effective treatments for various cancers is driving the cancer monoclonal antibodies market in Latin-America.
Latin America
Europe
Asia Pacific
Middle East
North America
Global Cancer Monoclonal Antibodies Market Segmentation
By Application
By Type of Antibody
- Murine Antibodies
- Humanized Antibodies
- Chimeric Antibodies
By Conjugation
- Immunocytokines
- Immunoliposome
- Radioimmunotherapy
- Antibody Directed Enzyme Prodrug Therapy(ADEPT)
By Distribution channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Frequently Asked Questions
The cancer monoclonal antibodies market is projected to expand at a CAGR of 11.8% during the forecast period
Merck & Co. Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), Spectrum Pharmaceuticals (U.S.), Eli Lilly and Company (U.S.), Amgen Inc. (U.S.), Bristol-Meyer Squibb (U.S.), Sanofi (France)
North America is the fastest-growing region for cancer monoclonal antibodies market
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
| 1.Executive Summary |
| 2.Global Cancer Monoclonal Antibodies Market Introduction |
| 2.1.Global Cancer Monoclonal Antibodies Market - Taxonomy |
| 2.2.Global Cancer Monoclonal Antibodies Market - Definitions |
| 2.2.1.Type of Antibody |
| 2.2.2.Application |
| 2.2.3.Conjugation |
| 2.2.4.Distribution channel |
| 2.2.5.Region |
| 3.Global Cancer Monoclonal Antibodies Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Cancer Monoclonal Antibodies Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Cancer Monoclonal Antibodies Market By Type of Antibody, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Murine Antibodies |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Humanized Antibodies |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Chimeric Antibodies |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 6.Global Cancer Monoclonal Antibodies Market By Application, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Breast Cancer |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Blood Cancer |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Liver Cancer |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Brain cancer |
| 6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Colorectal Cancer |
| 6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 6.6. Others |
| 6.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.6.3. Market Opportunity Analysis |
| 7.Global Cancer Monoclonal Antibodies Market By Conjugation, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. Immunocytokines |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Immunoliposome |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Radioimmunotherapy |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Antibody Directed Enzyme Prodrug Therapy(ADEPT) |
| 7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 8.Global Cancer Monoclonal Antibodies Market By Distribution channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. Hospital Pharmacies |
| 8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Retail Pharmacies |
| 8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Online Pharmacies |
| 8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 9.Global Cancer Monoclonal Antibodies Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 9.1. North America |
| 9.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.1.3. Market Opportunity Analysis |
| 9.2. Europe |
| 9.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.2.3. Market Opportunity Analysis |
| 9.3. Asia Pacific (APAC) |
| 9.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.3.3. Market Opportunity Analysis |
| 9.4. Middle East and Africa (MEA) |
| 9.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.4.3. Market Opportunity Analysis |
| 9.5. Latin America |
| 9.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.5.3. Market Opportunity Analysis |
| 10.North America Cancer Monoclonal Antibodies Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 10.1. Type of Antibody Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Murine Antibodies |
| 10.1.2.Humanized Antibodies |
| 10.1.3.Chimeric Antibodies |
| 10.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Breast Cancer |
| 10.2.2.Blood Cancer |
| 10.2.3.Liver Cancer |
| 10.2.4.Brain cancer |
| 10.2.5.Colorectal Cancer |
| 10.2.6.Others |
| 10.3. Conjugation Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Immunocytokines |
| 10.3.2.Immunoliposome |
| 10.3.3.Radioimmunotherapy |
| 10.3.4.Antibody Directed Enzyme Prodrug Therapy(ADEPT) |
| 10.4. Distribution channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Hospital Pharmacies |
| 10.4.2.Retail Pharmacies |
| 10.4.3.Online Pharmacies |
| 10.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.5.1.United States of America (USA) |
| 10.5.2.Canada |
| 11.Europe Cancer Monoclonal Antibodies Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 11.1. Type of Antibody Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Murine Antibodies |
| 11.1.2.Humanized Antibodies |
| 11.1.3.Chimeric Antibodies |
| 11.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Breast Cancer |
| 11.2.2.Blood Cancer |
| 11.2.3.Liver Cancer |
| 11.2.4.Brain cancer |
| 11.2.5.Colorectal Cancer |
| 11.2.6.Others |
| 11.3. Conjugation Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Immunocytokines |
| 11.3.2.Immunoliposome |
| 11.3.3.Radioimmunotherapy |
| 11.3.4.Antibody Directed Enzyme Prodrug Therapy(ADEPT) |
| 11.4. Distribution channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.Hospital Pharmacies |
| 11.4.2.Retail Pharmacies |
| 11.4.3.Online Pharmacies |
| 11.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.5.1.Germany |
| 11.5.2.France |
| 11.5.3.Italy |
| 11.5.4.United Kingdom (UK) |
| 11.5.5.Spain |
| 12.Asia Pacific (APAC) Cancer Monoclonal Antibodies Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 12.1. Type of Antibody Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Murine Antibodies |
| 12.1.2.Humanized Antibodies |
| 12.1.3.Chimeric Antibodies |
| 12.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Breast Cancer |
| 12.2.2.Blood Cancer |
| 12.2.3.Liver Cancer |
| 12.2.4.Brain cancer |
| 12.2.5.Colorectal Cancer |
| 12.2.6.Others |
| 12.3. Conjugation Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Immunocytokines |
| 12.3.2.Immunoliposome |
| 12.3.3.Radioimmunotherapy |
| 12.3.4.Antibody Directed Enzyme Prodrug Therapy(ADEPT) |
| 12.4. Distribution channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.Hospital Pharmacies |
| 12.4.2.Retail Pharmacies |
| 12.4.3.Online Pharmacies |
| 12.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.5.1.China |
| 12.5.2.India |
| 12.5.3.Australia and New Zealand (ANZ) |
| 12.5.4.Japan |
| 12.5.5.Rest of APAC |
| 13.Middle East and Africa (MEA) Cancer Monoclonal Antibodies Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 13.1. Type of Antibody Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Murine Antibodies |
| 13.1.2.Humanized Antibodies |
| 13.1.3.Chimeric Antibodies |
| 13.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Breast Cancer |
| 13.2.2.Blood Cancer |
| 13.2.3.Liver Cancer |
| 13.2.4.Brain cancer |
| 13.2.5.Colorectal Cancer |
| 13.2.6.Others |
| 13.3. Conjugation Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Immunocytokines |
| 13.3.2.Immunoliposome |
| 13.3.3.Radioimmunotherapy |
| 13.3.4.Antibody Directed Enzyme Prodrug Therapy(ADEPT) |
| 13.4. Distribution channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Hospital Pharmacies |
| 13.4.2.Retail Pharmacies |
| 13.4.3.Online Pharmacies |
| 13.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.5.1.GCC Countries |
| 13.5.2.South Africa |
| 13.5.3.Rest of MEA |
| 14.Latin America Cancer Monoclonal Antibodies Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 14.1. Type of Antibody Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.1.1.Murine Antibodies |
| 14.1.2.Humanized Antibodies |
| 14.1.3.Chimeric Antibodies |
| 14.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.2.1.Breast Cancer |
| 14.2.2.Blood Cancer |
| 14.2.3.Liver Cancer |
| 14.2.4.Brain cancer |
| 14.2.5.Colorectal Cancer |
| 14.2.6.Others |
| 14.3. Conjugation Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.3.1.Immunocytokines |
| 14.3.2.Immunoliposome |
| 14.3.3.Radioimmunotherapy |
| 14.3.4.Antibody Directed Enzyme Prodrug Therapy(ADEPT) |
| 14.4. Distribution channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.4.1.Hospital Pharmacies |
| 14.4.2.Retail Pharmacies |
| 14.4.3.Online Pharmacies |
| 14.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.5.1.Brazil |
| 14.5.2.Mexico |
| 14.5.3.Rest of LA |
| 15. Competition Landscape |
| 15.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 15.2.1.Merck & Co. Inc. |
| 15.2.2.F. Hoffmann-La Roche AG |
| 15.2.3.Spectrum Pharmaceuticals |
| 15.2.4.Eli Lilly and Company |
| 15.2.5.Amgen Inc. |
| 15.2.6.Bristol-Meyer Squibb |
| 15.2.7.Sanofi |
| 15.2.8.AstraZeneca |
| 16. Research Methodology |
| 17. Appendix and Abbreviations |
- Merck & Co. Inc.
- F. Hoffmann-La Roche AG
- Spectrum Pharmaceuticals
- Eli Lilly and Company
- Amgen Inc.
- Bristol-Meyer Squibb
- Sanofi
- AstraZeneca